Search PubMed⌕ Search

Biomedical subjects

T A Shapiro

Publications and source records attributed to T A Shapiro.

At least 37 records · Page 2Linked to original sources
PubMed1997

Biomechanical properties of human tibias in long-term spinal cord injury.

Long-term spinal cord injury (SCI) profoundly alters skeletal structure and function. In this study, the biomechanical properties of tibias from persons with SCI and from individuals closely matched in age and size but without SCI were quantified at both the structural and material levels. Nondestructive torsion tests were performed to determine apparent shear moduli for the tibia. The cortical thicknesses and polar moment of inertia were determined numerically. Four-point bending tests were performed to determine flexural modulus of elasticity on cortical bone specimens of the tibia. The apparent shear moduli of the SCI tibias were found to be lower than the non-SCI tibias (p < 0.05). The cortical thicknesses of the SCI tibias were significantly thinner than the control tibias (p < 0.05), while the polar moment of inertia showed no significant differences between control and SCI tibial cross sections (p > 0.05). The flexural modulus of elasticity of the cortical bone specimens were lower in the SCI tibias than the controls (p < 0.05). These differences suggest that tibias may undergo micro-structural changes as well as structural adaptation following SCI, which alter their mechanical properties.

Aged↗
PubMed1996

Topoisomerases in kinetoplastids.

Topoisomerases are enzymes that mediate topological changes in DNA that are essential for nucleic acid biosynthesis and for cell survival. The kinetoplastid protozoa, which include pathogenic trypanosomes and Leishmania, have yielded an interesting variety of purified topoisomerase activities as well as several topoisomerase genes. In these parasites, topoisomerases are involved in the metabolism of both nuclear and mitochondrial (kinetoplast) DNA. In this review, Christian Burri, Armette Bodley and Theresa Shapiro summarize what is known about topoisomerases in kinetoplastids, and consider the intriguing possibility that these enzymes may act as valuable antiparasite drug targets.

Journal Article↗
PubMed1995

Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.

African trypanosomes (Trypanosoma brucei species) are parasitic protozoa that cause lethal diseases in humans and cattle. Previous studies showed that camptothecin, a potent and specific inhibitor of DNA topoisomerase I, is cytotoxic to African trypanosomes and related pathogenic hemoflagellates (Bodley AL and Shapiro TA, Proc Natl Acad Sci USA 92: 3726-3730, 1995). In this study, a series of camptothecin analogs was tested against axenically cultured, bloodstream form, T. brucei. Modifications to the pentacyclic nucleus of camptothecin ablated antiparasitic activity. In contrast, activity could be increased by substituents added to the parent ring system (e.g. 10,11-methylenedioxy or ethylenedioxy groups; alkyl additions to carbon 7; or 9-amino or 9-chloro substituents). Cytotoxicity was correlated with the level of cleavable complexes in trypanosomes, implicating topoisomerase I as the intracellular target for these compounds. To obtain some indication of selective toxicity, ten compounds were also tested against L1210 mouse leukemia cells. The 9-substituted-10,11-methylenedioxy analogs caused a disproportionate increase in antiparasitic activity, compared with mammalian cell toxicity. These findings provide a basis for designing further structural modifications and for selecting camptothecin analogs to test in animal models of trypanosomiasis.

Animals↗
PubMed1995

Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.

Parasites pose a threat to the health and lives of many millions of human beings. Among the pathogenic protozoa, Trypanosoma brucei, Trypanosoma cruzi, and Leishmania donovani are hemoflagellates that cause particularly serious diseases (sleeping sickness, Chagas disease, and leishmaniasis, respectively). The drugs currently available to treat these infections are limited by marginal efficacy, severe toxicity, and spreading drug resistance. Camptothecin is an established antitumor drug and a well-characterized inhibitor of eukaryotic DNA topoisomerase I. When trypanosomes or leishmania are treated with camptothecin and then lysed with SDS, both nuclear and mitochondrial DNA are cleaved and covalently linked to protein. This is consistent with the existence of drug-sensitive topoisomerase I activity in both compartments. Camptothecin also inhibits the incorporation of [3H]thymidine in these parasites. These molecular effects are cytotoxic to cells in vitro, with EC50 values for T. brucei, T. cruzi, and L. donovani, of 1.5, 1.6, and 3.2 microM, respectively. For these parasites, camptothecin is an important lead for much-needed new chemotherapy, as well as a valuable tool for studying topoisomerase I activity.

Animals↗
PubMed1995

Drug cytotoxicity assay for African trypanosomes and Leishmania species.

The trypanosomes and Leishmania species are parasitic protozoa that afflict millions of people throughout the world. If not treated, African trypanosomiasis and visceral leishmaniasis are fatal. The available drugs are severely limited by toxicity, marginal efficacy, the requirement for parenteral administration, and spreading drug resistance. In this study, a spectrophotometric assay was developed and validated for measuring the cytotoxicity of test compounds against axenically cultured bloodstream-form Trypanosoma brucei (African trypanosomes) and promastigotes of Leishmania donovani. Enzymatic hydrolysis of p-nitrophenyl phosphate, monitored by a microtiter plate reader, is a reliable surrogate for parasite cell counts. The assay is simple, inexpensive, and highly reproducible. The coefficient of variation for EC50 values is < 10% for determinations obtained over several months. This method permits the rapid screening of candidates for much-needed new drugs against these parasites.

Acid Phosphatase↗
PubMed1995

The structure and replication of kinetoplast DNA.

The mitochondrial DNA of trypanosomatid protozoa, termed kinetoplast DNA (kDNA), is unique in its structure, function, and mode of replication. kDNA is a massive network, composed of thousands of topologically interlocked DNA circles, which resembles the chain mail of medieval armor. Each cell contains one network condensed into a disk-shaped structure within the matrix of its single mitochondrion. The kDNA circles are of two types, maxicircles present in a few dozen copies and minicircles present in several thousand copies. The maxicircles, which encode ribosomal RNAs and a few mitochondrial proteins, are similar in structure and genetic function to the mitochondrial DNA of other eukaryotes. Many maxicircle transcripts undergo editing, a remarkable process involving the insertion or deletion of uridine residues at specific sites. The minicircles encode small guide RNAs that control the specificity of editing. During kDNA replication, covalently closed minicircles are released from the network by a topoisomerase II. The free minicircles replicate as theta-structures within one of two complexes of replication proteins that are positioned on opposite sides of the kinetoplast disk. The progeny minicircles, which contain nicks or gaps, are attached to the network periphery. Maxicircles also replicate as theta-structures, but they remain linked to the network. As replication proceeds, the number of minicircles and maxicircles increases. When the network has doubled in size, all of the minicircle nicks and gaps are repaired, and the network splits in two. The two progeny networks then segregate into the daughter cells.

Animals↗
PubMed1994

Mitochondrial topoisomerase II activity is essential for kinetoplast DNA minicircle segregation.

Etoposide, a nonintercalating antitumor drug, is a potent inhibitor of topoisomerase II activity. When Trypanosoma equiperdum is treated with etoposide, cleavable complexes are stabilized between topoisomerase II and kinetoplast DNA minicircles, a component of trypanosome mitochondrial DNA (T. A. Shapiro, V. A. Klein, and P. T. Englund, J. Biol. Chem. 264:4173-4178, 1989). Etoposide also promotes the time-dependent accumulation of small minicircle catenanes. These catenanes are radiolabeled in vivo with [3H]thymidine. Dimers are most abundant, but novel structures containing up to five noncovalently closed minicircles are detectable. Analysis by two-dimensional gel electrophoresis and electron microscopy indicates that dimers joined by up to six interlocks are late replication intermediates that accumulate when topoisomerase II activity is blocked. The requirement for topoisomerase II is particularly interesting because minicircles do not share the features postulated to make this enzyme essential in other systems: for minicircles, the replication fork is unidirectional, access to the DNA is not blocked by nucleosomes, and daughter circles are extensively nicked and (or) gapped.

Animals↗
PubMed1994

In vivo inhibition of trypanosome mitochondrial topoisomerase II: effects on kinetoplast DNA maxicircles.

Kinetoplast DNA, the mitochondrial DNA of trypanosomes, is a topologically complex structure composed of interlocked minicircles and maxicircles. We previously reported that etoposide, a potent inhibitor of topoisomerase II, promotes the cleavage of about 20% of network minicircle DNA (T. A. Shapiro, V. A. Klein, and P. T. Englund, J. Biol. Chem. 264:4173-4178, 1989). We now find that virtually all maxicircles are released from kinetoplast DNA networks after trypanosomes are treated with etoposide. As expected for a topoisomerase II cleavage product, the linearized maxicircles have protein bound to both 5' ends. After etoposide treatment, the residual minicircle catenanes have a sedimentation coefficient which is only 70% that of controls, and by electron microscopy the networks are less compact. Double-size networks, the characteristic dumbbell-shape forms that normally arise in the final stages of network replication, are replaced by aberrant unit-size forms.

Animals↗
PubMed1993

Kinetoplast DNA maxicircles: networks within networks.

Kinetoplast DNA (kDNA), the mitochondrial DNA of trypanosomes, is an enormous network of interlocked minicircles and maxicircles. We selectively removed minicircles from Trypanosoma equiperdum kDNA networks by restriction enzyme cleavage. Maxicircles remained in aggregates that were resistant to protease or RNase and contained no residual minicircles, but were resolved into circular monomers by topoisomerase II. Maxicircles thus form independent catenanes within kDNA networks. Heterogeneity in the size, composition, and organization of maxicircle catenanes reflects changes that occur during kDNA replication. The rosette-like arrangement of maxicircle catenanes is distinctly different from that of minicircle catenanes. Trypanosome kDNA networks reveal unique topological complexity: they are composed of entirely dissimilar catenanes that are in turn extensively interlocked with one another.

Animals↗
PubMed1993

Prolonged heparin therapy for occlusive intracoronary thrombus.

The presence of intracoronary thrombus is associated with increased complications during coronary angioplasty. Such thrombus may also mimic the appearance of a critical stenosis. We report a case of nearly occlusive intracoronary thrombus which resolved after prolonged heparin therapy, revealing only a minimal underlying stenosis. The recognition and treatment of this entity is discussed.

Coronary Angiography↗
PubMed1993

Inhibition of topoisomerases in African trypanosomes.

African trypanosomiasis continues to pose a challenge for the development of new chemotherapy. Type II topoisomerases, essential enzymes in nucleic acid metabolism, have proven highly suitable as targets for antibacterial and antitumor therapy. Well-characterized topoisomerase II inhibitors affect the cognate nuclear and mitochondrial enzymes in Trypanosoma equiperdum. Inhibition is accompanied by extensive fragmentation and structural alteration in nuclear and mitochondrial DNA. Some clinically important antitrypanosomal drugs bind to DNA (i.e., pentamidine, isometamidium, diminazene). These agents inhibit the mitochondrial, but not nuclear, topoisomerase II of trypanosomes. These studies suggest that type II topoisomerase inhibitors may prove to be effective and safe new antitrypanosomal drugs.

Animals↗
PubMed1993

Effects of probenecid on the pharmacokinetics of allopurinol riboside.

Allopurinol riboside is an experimental agent for the treatment of leishmaniasis and American trypanosomiasis. Previous studies showed that after oral administration, unexpectedly low levels of allopurinol riboside in plasma are attributable to incomplete absorption and rapid renal clearance. In this randomized, crossover evaluation in healthy volunteers, probenecid reduces the renal clearance of allopurinol riboside, extends the half-life of allopurinol riboside in plasma, and triples the levels of allopurinol riboside in plasma.

Adult↗
PubMed1992

Coronary angiography and interventional cardiology.

Percutaneous transluminal coronary angioplasty has become the most commonly applied coronary revascularization procedure. Its growth is due to expanding indications and new patient populations including patients with multivessel coronary artery disease, acute myocardial infarction or cardiogenic shock, and elderly patients. Success rates and complications for percutaneous transluminal coronary angioplasty have remained the same or improved despite the expanding indications and the persistent problem of restenosis. Several recent studies have examined new biologic approaches to restenosis. However, the most exciting area of interventional cardiology continues to be the use and development of new mechanical devices including stents, lasers, and atherectomy for unfavorable anatomic lesions, acute occlusion after angioplasty, and to prevent restenosis. The gold standard in the assessment of coronary disease is still angiography, but newer imaging techniques including intravascular ultrasound and angioscopy have added to our understanding of angioplasty, unstable angina, and the use of new devices.

Angioplasty, Balloon, Coronary↗
PubMed1991

Pharmacokinetics and metabolism of allopurinol riboside.

There are no safe and effective oral drugs to treat leishmaniasis and Chagas' disease. The safety, pharmacokinetics, and metabolism of single and multiple oral doses of allopurinol riboside, an investigational antiparasitic agent, were evaluated in a randomized, double-blinded, placebo-controlled study in 32 healthy male volunteers, at levels up to 25 mg/kg q.i.d. for 13 doses. No significant toxicity was detected. Allopurinol riboside peaks in plasma 1.6 hours after administration, has an elimination half-life of 3 hours, and steady-state concentrations in the therapeutic range. However, in contrast to preclinical studies in dogs (plasma levels proportional to oral doses up to 200 mg/kg), we found that plasma levels were unexpectedly low and did not rise with increasing dose. Furthermore, allopurinol and oxypurinol (unanticipated metabolites) were detected at levels proportional to the dose of allopurinol riboside. We present a model that includes incomplete absorption, metabolism of residual drug by enteric flora, and absorption of bacterial metabolites to explain these findings in humans.

Adolescent↗
PubMed1990

Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs.

Pentamidine, diminazene aceturate (Berenil), isometamidium chloride (Samorin), and ethidium bromide, which are important antitrypanosomal drugs, promote linearization of Trypanosoma equiperdum minicircle DNA (the principal component of kinetoplast DNA, the mitochondrial DNA in these parasites). This effect occurs at therapeutically relevant concentrations. The linearized minicircles are protease sensitive and are not digested by lambda exonuclease (a 5' to 3' exonuclease), indicating that the break is double stranded and that protein is bound to both 5' ends of the molecule. The cleavage sites map to discrete positions in the minicircle sequence, and the cleavage pattern varies with different drugs. These findings are characteristic for type II topoisomerase inhibitors, and they mimic the effects of the antitumor drug etoposide (VP16-213, a semisynthetic podophyllotoxin analog) on T. equiperdum minicircles. However, the antitrypanosomal drugs differ dramatically from etoposide in that they do not promote detectable formation of nuclear DNA-protein complexes or of strand breaks in nuclear DNA. Selective inhibition of a mitochondrial type II topoisomerase may explain why these antitrypanosomal drugs preferentially disrupt mitochondrial DNA structure and generate dyskinetoplastic trypanosomes (which lack mitochondrial DNA).

Animals↗
PubMed1989

Drug-promoted cleavage of kinetoplast DNA minicircles. Evidence for type II topoisomerase activity in trypanosome mitochondria.

Minicircle DNA, the major component of the mitochondrial DNA of trypanosomes (kinetoplast DNA), is linearized when living Trypanosoma equiperdum cells are treated with inhibitors of mammalian type II topoisomerases and then lysed with sodium dodecyl sulfate. A variety of intercalating and nonintercalating compounds (the epipodophyllotoxins, 4'-(9-acridinylamino)-methanesulfon-m-anisidine, 2-methyl-9-hydroxyellipticine, and acriflavine) are active, but novobiocin and specific gyrase inhibitors (the quinolones) are not. The linearized minicircles are in a DNA-protein complex, as their electrophoretic mobility is increased by Proteinase K treatment. They are digested by exonuclease III but not by lambda exonuclease, indicating that the protein must be linked to both 5' ends. Drug-induced cleavage sites vary with different compounds and are found throughout the minicircle sequence. These results indicate that trypanosome mitochondria contain a type II topoisomerase with some properties similar to those of type II topoisomerases in the nucleus of higher eukaryotes. A maximum of 12% of all minicircles is cleaved in the presence of VP16-213, indicating there are at least 600 molecules of mitochondrial type II topoisomerase/cell or about one enzyme/8 kilobases of minicircle DNA.

Animals↗